MoonLake Immunotherapeutics MLTX Other comprehensive income (loss)
Other comprehensive income (loss) at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTax.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's other comprehensive income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's other comprehensive income (loss)?
- MoonLake Immunotherapeutics (MLTX) reported other comprehensive income (loss) of -$282K in Q1 2026.
- How has MoonLake Immunotherapeutics's other comprehensive income (loss) changed year-over-year?
- MoonLake Immunotherapeutics's other comprehensive income (loss) increased by 89.4% year-over-year, from -$2.66M to -$282K.
- What is the long-term trend for MoonLake Immunotherapeutics's other comprehensive income (loss)?
- Over 2 years (2022 to 2025), MoonLake Immunotherapeutics's other comprehensive income (loss) has grown at a 169.6% compound annual growth rate (CAGR), from $660.65K to -$4.8M.
- What does other comprehensive income (loss) mean?
- This metric aggregates all non-owner changes in equity that are excluded from the traditional net income statement, such as unrealized gains or losses on investments and actuarial adjustments. It provides a more comprehensive view of the company's total financial performance and changes in equity over a specific period. Investors use this to assess the broader economic impact on the company's balance sheet beyond operational results.